{"id":31054,"date":"2012-12-16T18:00:35","date_gmt":"2012-12-16T23:00:35","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=31054"},"modified":"2012-12-16T15:30:16","modified_gmt":"2012-12-16T20:30:16","slug":"what-they-do","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2012\/12\/16\/what-they-do\/","title":{"rendered":"what they do…"},"content":{"rendered":"
\n
\n
Supreme Court takes up case on generic drugs<\/a>
Politico<\/font><\/strong>
By BRETT NORMAN
12\/10\/12<\/div>\n

\"The Supreme Court will take up “pay for delay” — the multibillion-dollar dispute over whether brand-name drug makers should be able to pay generic drug companies for agreeing to delay putting cheaper versions on the market. The justices agreed Friday to hear the case of Federal Trade Commission v. Watson Pharmaceuticals<\/em> and two other cases to resolve conflicting rulings in lower courts. Both the pharmaceutical industry and the FTC requested a Supreme Court review to resolve a long-running battle antitrust regulators have labeled “pay-for-delay” settlements. “This is the health care reform case of 2013,” said David Balto, a former FTC policy director who helped file the first lawsuit against pay-for-delay deals back in the 1990s. “There’s no other case that can have as much impact on reducing health care costs.”<\/strong><\/sup><\/p>\n

The FTC has estimated the deals cost consumers $3.5 billion annually by delaying access to cheaper generics, an estimate disputed by pharmaceutical companies. The Congressional Budget Office estimated that legislation introduced to restrict the deals would save the government more than $2.5 billion over 10 years in federal health care spending. Both the generic and name-brand pharmaceutical industries defend the settlements. They say the deals are an efficient and, from a business perspective, predictable alternative to the uncertainty about expensive patent lawsuits fought to the bitter end.<\/strong><\/sup><\/p>\n

The drug industry argues that in all cases, generics come on the market before the original patents expire and sometimes sooner than they would have even in the case of a successful patent challenge. But FTC Chairman Jon Leibowitz has made the delay-deals a signature issue, arguing that they illegally prop up profits for drug companies at the expense of consumers. And in July, the U.S. Court of Appeals for the 3rd Circuit sided with the FTC, upsetting more than 10 years of precedent upholding the arrangements…<\/strong><\/sup><\/p>\n

The FTC challenged the settlement as anti-competitive. A district court rejected the claim. In April, the U.S. Court of Appeals for the 11th Circuit did as well, ruling that as long as the patent settlement did not extend exclusive rights beyond the patent expiration date, it was immune to antitrust violations. The FTC asked the Supreme Court to settle the issue, and 31 states filed a brief in support of the suit. Both the generic and brand-name drug companies involved asked the high court to weigh in as well. On Friday, the Supreme Court agreed to review the cases from both the 3rd and 11th circuits.<\/strong><\/sup><\/div>\n<\/blockquote>\n
\"FischerMy interest on this blog is how the business of the pharmaceutical industry massively intruded on psychiatry in the specific and the practice of medicine in general during my years as a physician. Just a piece of background: my choice of medicine had something to do with an aversion to business – well earned in early life and only moderately treatable with psychoanalysis, so the business side of things is not my forte. I owe any personal success in that arena to a good marital choice, made primarily on other grounds.<\/em> <\/div>\n

Once a drug is approved by the FDA, the pharmaceutical company is granted a period of exclusivity during which only they can manufacture and sell the drug – a patent with limited duration. It’s a compromise between giving them the right to profit from their investment in development and giving the consumer a break in cost with generics after the original exclusivity runs out. The company can extend exclusivity by making good faith testing in children. The obvious inadvertent consequence is that the time limit of the life cycle<\/em> of a drug incentivizes the kind of deceitful marketing campaigns that minimize or even hide risk and make false claims of efficacy. It’s a sprint to achieve maximal profit in the time allowed. <\/p>\n

Several years ago, when I first got focused all of this, I was naive about the whole process. So I was shocked when I read this response from AstraZeneca – <\/div>\n
 <\/div>\n
– shocked that Sales and Marketing<\/font><\/strong> was actually directing research [I find it hard to even remember being that naive]. Once FDA Approval is behind them, the race is on, playing chess with competitors to win the ears of prescribing physicians and consumers. The resulting clinical research has been labeled experimercials<\/em>. This "pay for delay" is a gambit I didn’t know about. Since the patent holder can continue to sell the drug for a high price, paying the generic manufacturer to delay is a win·<\/strong>win proposition – profitable for both parties. There are many other plays – indication sprawl, off label promotion, clinical guidelines, flooding the literature, programs like TMAP. I’m not business-savvy enough to even create a comprehensive list:<\/div>\n
\"Knights<\/div>\n
The game of Chess is in at least its second millenium – a paradigm for human strategic thought, whether one on one in the marketplace or in the high stakes games of war and peace. It reduces strategy to basic elements – risk, power, position, moves and counter moves. Expert players play not only each other, but by proxy, against the great players throughout history – endlessly poring over their recorded games. They rarely play novices – too boring. Stealth is a big factor in the play, but it’s stealth in plain view, unlike card games or the strategies of real life<\/em>. The game of chess will probably always be with us because it’s also a paradigm for fair play. The sides are equal by definition. It’s played in an enclosed space and the rules are non-negotiable. The only variable is strategic expertise.<\/div>\n

This "pay to delay" strategy seems odious to me, messing with rules clearly put in place to protect individual sick people as consumers and keep national healthcare costs in check – protecting a captive audience from exploitation. But you know what? it’s none of my business<\/em>. I can make sure to only recommend drugs when indicated, and keep up with the science of safety and efficacy – using generics whenever possible to do my part in containing healthcare costs and working for my patient. But the chess game in the business<\/em> arena is not my business<\/em> as a physician. The covenant between doctor and patient says that I’m bringing expertise to the patient in their chess game with disease. The chess game between pharmaceutical companies and cost accounting regulators is for other experts.<\/p>\n

But this article did bring up something that is my business<\/em>. Why is the Supreme Court involved in this tedious trivia? In my mind, this is just game playing, capitalizing on a loophole. It’s worth a 15 yard penalty or some new book of statutes to close the loophole before it spreads [which it will]. But if the Supreme Court needs something to think about, why not take on the pharmaceutical industry for paying medical experts to be salesmen? or masterminding false advertizing in medical journals? or perhaps taking on participating physicians? or calling the medical profession [which claims to be self-regulating] to task for not stopping these buy-an-expert schemes? In the area of law enforcement, taking bribes or kickbacks is a crime. So is tampering with evidence. Police Departments have sections called Internal Affairs. In the practice of medicine, we have malpractice suits and people losing their licenses for stepping over ethical lines. But in academic or organized medicine, we have a subset of obviously "dirty KOLs" who seem to operate with impunity. Even when they step way WAY over the line, they are allowed to stay in the game. A recent APA President was under congressional investigation and exposed as signing on to a ghost-written textbook, one who was already in question for his involvement in a medical corporation that was all entwined with his university. <\/p>\n

I have little interest in any more involvement of government in medicine, but without the threat of real oversight, this corruption of the covenant between physicians and patients is likely to continue. There are just too many players and too much money involved. I suppose that an analogy might be priests and other religious figures – relying on some kind of intrinsic morality to regulate things. We’ve recently seen where that kind of hands off policy has gotten us in the religious arena. The combination of the self-serving motives of the pharmaceutical, managed care, insurance, and hospital corporation industries in the practice of medicine  is a international disgrace. But adding the corruption of academic and organized medicine to the mix is a multiplier of a problem already out of hand. By and large, practicing physicians and patients have become the pawns in a chess game that takes us far afield from the primary focus on the healthcare of individual patients.<\/p>\n

If we’re going to take a case to the Supreme Court, how about finding one that broadly addresses the interface between commercial industrial interests and good medical practice? How about some cases charging influence peddling? What about a suit that addresses what constitutes bribery or payola in the halls of medical academia? It was never intended to be the game of chess it’s become. It’s a time honored contract broken at high enough levels to warrant an equally high level scrutiny and review. We appear to be moving towards the position that health care is a right, rather than a commodity. If that’s the case, it’s right down the Supreme Court’s alley. That’s what they do…<\/div>\n","protected":false},"excerpt":{"rendered":"

Supreme Court takes up case on generic drugs Politico By BRETT NORMAN 12\/10\/12 The Supreme Court will take up “pay for delay” — the multibillion-dollar dispute over whether brand-name drug makers should be able to pay generic drug companies for agreeing to delay putting cheaper versions on the market. The justices agreed Friday to hear […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-31054","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/31054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=31054"}],"version-history":[{"count":40,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/31054\/revisions"}],"predecessor-version":[{"id":31104,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/31054\/revisions\/31104"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=31054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=31054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=31054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}